Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211,135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.
Bonate PL, Van Sant C, Cho K, Zook EC, Smith LR, Boutsaboualoy S, Ye M, Wang X, Wu R, Koester A, Rammelsberg D, Goldwater R, Marbury TC. Bonate PL, et al. Among authors: wang x. Clin Pharmacol Drug Dev. 2020 May;9(4):444-455. doi: 10.1002/cpdd.792. Epub 2020 Mar 23. Clin Pharmacol Drug Dev. 2020. PMID: 32202705 Clinical Trial.
Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X, Bai W, Ren M, Kim T, Lee JY, Chuang FC, Wang PH, He W, Ma X, Miyazaki K, Song N, Wang X, Yu Q. Ruan X, et al. Among authors: wang x, wang ph. J Int Med Res. 2024 May;52(5):3000605241247684. doi: 10.1177/03000605241247684. J Int Med Res. 2024. PMID: 38818888 Free PMC article. Clinical Trial.
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.
Schaudig K, Wang X, Bouchard C, Hirschberg AL, Cano A, Shapiro C M M, Stute P, Wu X, Miyazaki K, Scrine L, Nappi RE. Schaudig K, et al. Among authors: wang x. BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525. BMJ. 2024. PMID: 39557487 Free PMC article. Clinical Trial.
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.
Shapiro C M M, Wu X, Wang X, Miyazaki K, Morga A, Nappi RE, Stute P, Martins K, Schaudig K. Shapiro C M M, et al. Among authors: wang x. Maturitas. 2025 Feb;193:108159. doi: 10.1016/j.maturitas.2024.108159. Epub 2024 Nov 26. Maturitas. 2025. PMID: 39809112 Free article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 38564451
Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study.
Shoji J, Goggins WC, Wellen JR, Cunningham PN, Johnston O, Chang SS, Solez K, Santos V, Larson TJ, Takeuchi M, Wang X. Shoji J, et al. Among authors: wang x. Transplantation. 2024 Aug 1;108(8):1782-1792. doi: 10.1097/TP.0000000000004985. Epub 2024 Jul 20. Transplantation. 2024. PMID: 39042770 Free PMC article. Clinical Trial.
211,135 results
You have reached the last available page of results. Please see the User Guide for more information.